NCT06289517

PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression

A Study to Evaluate 68Ga-Her2-affibody PET/CT Imaging of Her2 Expression in Tumors

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status of HER2, aiming to provide a new imaging method for the determination of HER2 status in breast cancer At the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.

Detailed description

This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status of HER2 in whole body cancer lesions, aiming to provide a new imaging method for the determination of HER2 status in breast cancer and supplement more overall information that is difficult to obtain by traditional core needle biopsy. At the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.

Conditions

• Neoplasms

Interventions

Type	Name	Description
DRUG	68Ga-Her2-affibody	68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.

Timeline

• Start date: 2024-05-28
• Primary completion: 2025-07-30
• Completion: 2025-08-30
• First posted: 2024-03-04
• Last updated: 2024-12-18

Locations

1 site across 1 country: China